We report a Japanese patient with familial Mediterranean fever (FMF) 
Introduction

Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized clinically by recurrent attacks of fever, peritonitis, pleuritis and/or polyarthritis, and genetically by autosomal recessive inheritance (1). The MEFV gene encoding marenostrin/pyrin is responsible for this disease (2). As frequent attacks of inflammation often result in the development of renal amyloidosis with a poor prognosis, colchicine is most commonly employed for treatment of FMF (2). When this drug is ineffective or cannot be used because of adverse effects, such as diarrhea and bone marrow suppression, other pharmacotherapies are considered as the next therapeutic option
. Allogeneic bone marrow transplantation has also been shown to be effective in the prevention of FMF attacks (9) . Several recent reports have demonstrated that the anti-tumor necrosis factor (TNF)-α monoclonal antibody, infliximab, reduces the frequency of FMF attacks in Spanish and Turkish patients (10, 11 
F i g u r e 1 . Cl i n i c a l c o u r s e o f t h e p a t i e n t . T h e f r e q u e n c y o f f e b r i l e a t t a c k s wi t h t h o r a c o a b d o mi n a l p a i n a n d p o l y a r t h r a l g i a d r a ma t i c a l l y d e c r e a s e d a f t e r s t a r t i n g i n f l i x i ma b a n d l o w-d o s e me t h o t r e x a t e . CRP : C-r e a c t i v e p r o t e i n .
such as C-reactive protein, on routine laboratory data performed during febrile attacks. At age 33 the patient was referred to our hospital, and was diagnosed as having FMF based on clinical symptoms typical of this disease and a compound heterozygosity for marenostrin/pyrin variant E148
Q/M694I as shown in our previous report (8) (Fig. 1) (Fig. 1 ). There were no adverse events ascribable to infliximab.
general status of our patient improved in parallel with a decrease in the severity and frequency of febrile attacks after the third administration of infliximab. Febrile attacks with thoracoabdominal pain and polyarthralgia completely disappeared even during menstruation after the fourth administration of this drug. Serum levels of TNF-α and interleukin (IL)-1β just before and 3 weeks after starting infliximab were within normal limits (< 5 pg/ml). Methotrexate was stopped approximately 9 months after commencement because of gastrointestinal symptoms, but the patient has since remained in good general condition with no FMF attacks for 6 months under infusion of infliximab alone at 2-month intervals
Discussion
It has been proposed that pro-inflammatory stimuli, such as inflammatory cytokines, the autonomic nervous system, hormones or some types of stress, are normally balanced by marenostrin/pyrin expressed on mature neutrophils (1, 2) .
Disruption of this balance by mutations in the MEFV gene could easily cause microtubular activation and migration of neutrophils, resulting in FMF attacks (2). According to a recent report mutations at position 694 of the MEFV gene have a crucial role in development of FMF but also in showing a severe phenotype (13). The present patient showed a heterozygous mutation of M694I, and additional effects of E148Q may have caused clinical symptoms typical of FMF (8).
Colchicine is widely used for treatment of FMF with regard to its ability to strongly inhibit neutrophil chemotaxis (2) . In the present patient, however, colchicine and other anti-inflammatory drugs were ineffective or could not be used because of adverse effects, while the combination therapy with infliximab and low-dose methotrexate completely controled FMF attacks. There were two reasons for using low-dose methotrexate in our patient. One is that she showed polyarthralgia uncontrollable by non-steroidal antiinflammatory drugs during FMF attacks. Methotrexate is a key drug for rheumatoid arthritis, but may be effective also for polyarthralgia in FMF attacks (11) . The other is that infliximab is a chimeric drug of human and mouse origin. To avoid the production of neutralizing antibodies to infliximab, low-dose methotrexate has to be coadministered in Japan based on clinical experience in rheumatoid arthritis (14) . Methotrexate was stopped 9 months after commencement because of adverse effects in our patient, but no FMF attacks with polyarthralgia have since occurred for 6 months with infliximab therapy alone. These findings suggest that infliximab may play a central role in suppressing FMF attacks as shown in a recent report (11) . Etanercept, which is another TNF antagonist available in Japan, has also been shown to suppress FMF attacks (15, 16) 
